Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells

Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells

One mechanism of resistance of prostate cancer (PCa) to enzalutamide (MDV3100) treatment is the increased expression of AR variants lacking the ligand binding-domain, the best characterized of which is AR-V7. We have previously reported that Phosphatidylinositol-4-phosphate 5-kinase alpha (PIP5Kα),...

Full description

Bibliographic Details
Main Authors: Sarwar, Martuza, Semenas, Julius, Miftakhova, Regina, Simoulis, Athanasios, Robinson, Brian, Wingren, Anette Gjörloff, Mongan, Nigel P., Heery, David M., Johnsson, Heather, Abrahamsson, Per-Anders, Dizeyi, Nishtman, Luo, Jun, Persson, Jenny L.
Format: Article
Published: Impact Journals 2016
Subjects:
Prostate Cancer Metastasis
Enzalutamide Resistance
Lipid Kinase Inhibitor
AR-V7
PIP5K1α
Online Access:https://eprints.nottingham.ac.uk/36657/

Internet

https://eprints.nottingham.ac.uk/36657/

Similar Items